Amount of postoperative blood loss (mL) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
1 finding from 1 review
Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
1 study · 28 participants
GRADE not reported
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
M + GLP1‐A
2 findings from 1 review
M + DPP4‐I
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).
3 findings from 1 review
RR 2.21 [0.74, 6.58]
4 studies · 5093 participants
Very low
no estimate extracted
1 study · 64 participants
Very low
RR 1.32 [0.76, 2.28]
9 studies · 11694 participants
Low
M + thiazolidinedione
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).
2 findings from 1 review
M + nateglinide
4 findings from 1 review
no estimate extracted
1 study · 233 participants
Very low
no estimate extracted
3 studies · 874 participants
Low
no estimate extracted
2 studies · 446 participants
Low
Show 1 more finding
M + SGLT2‐I
It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).
2 findings from 1 review
Health‐related quality of life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐fatal stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
1 finding from 1 review
Global state ‐ number of participants with relapse/exacerbations of psychosis (combined time points) · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
Summary of findings table ‐ Cognitive behavioural therapy plus… showed no clear difference in global state ‐ number of participants with relapse/exacerbations of… compared with control (low certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
Summary of findings table ‐ Cognitive behavioural therapy plus… showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with control (moderate certainty).
1 finding from 1 review
Functioning at · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
1 finding from 1 review
Risk for at least one adverse event per patient · recent‐onset psychosis (less than three years since the start of psychotic symptoms and either first or second psychotic episode)
It is very uncertain whether summary of findings table ‐ Cognitive behavioural therapy plus… changes adverse events ‐ participants with at least one adverse event ‐ < 12… compared with control (very low certainty).
1 finding from 1 review
Number with frequent relapses by 12 to 24 months stratified by risk of selection bias: Low risk of selection bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in subgroup analysis by risk of bias for number with frequent relapses:… compared with three months (high certainty).
1 finding from 1 review
Subgroup analysis by risk of bias for number with frequent relapses: Unclear or high risk of selection bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… probably leads to lower subgroup analysis by risk of bias for number with frequent relapses:… compared with three months (moderate certainty).
1 finding from 1 review
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: hypertension compared with three months (moderate certainty).
1 finding from 1 review
Adverse events: eye complications · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: eye complications compared with three months (moderate certainty).
1 finding from 1 review
Adverse events: Cushingoid appearance · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: Cushingoid appearance compared with three months (moderate certainty).
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: psychological disorders compared with three months (low certainty).
1 finding from 1 review